ロード中...
Cost‐Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma
BACKGROUND. Treatment options for patients with platinum‐refractory, recurrent, metastatic head and neck squamous cell carcinoma (r/m HNSCC) are limited and prognosis is poor. The recent CheckMate 141 clinical trial demonstrated that nivolumab, an anti‐programmed cell death protein 1 monoclonal anti...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AlphaMed Press
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5813741/ https://ncbi.nlm.nih.gov/pubmed/29021380 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0277 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|